Industry / Bahrain
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
Wyeth's Lead Vaccine Added To Six More National Immunisation Programmes
July 2008 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
Sales for Wyeth's Prevenar PCV7 (7-valent pneumococcal saccharide conjugated vaccine) are to be given a boost after it was added to national immunisation programmes in six countries in Europe and the Middle East. Since 2000, when the vaccine was first launched in the US, where it is known as Prevnar, it has gained access to 88 markets. With the addition of Bahrain, Cyprus, Hungary, Ireland, Slovakia and Sweden, Prevenar is now included in 24 national immunisation programmes.